3D Bioprinting Market Report 2025

This 3D Bioprinting market report covers market characteristics, size & growth, segmentation, regional & country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The 3D bioprinting market size has grown rapidly in recent years. It will grow from $1.86 billion in 2024 to $2.21 billion in 2025 at a compound annual growth rate (CAGR) of 19.1%. The growth in the historic period can be attributed to research and development funding, growth in chronic diseases, organ shortage, rise in pharmaceutical testing, growth in tissue engineering.

The 3D bioprinting market size is expected to see exponential growth in the next few years. It will grow to $5.11 billion in 2029 at a compound annual growth rate (CAGR) of 23.3%. The growth in the forecast period can be attributed to healthcare advancements, rising development of bioprinted skin, growing awareness among patients, aging population. Major trends in the forecast period include multi-material printing, vascularization techniques, organ-on-a-chip, custom implants, biofabrication in space.

Rising governments and private funding to support 3D bioprinting research activities are expected to drive the growth of the 3D bioprinting market in the forecast period. 3D bioprinting is increasing applications in healthcare attracted funding from government and private organizations. This funding provides financial and technical assistance across different development phases of 3D bioprinting techniques. For instance, in May 2022, Readily3d SA, a Switzerland-based bioprinting company, received funding of $600,000 from the European Union to develop a living miniature model of the pancreas using its Tomolite 3D bioprinting technique. The Australian Minister for Health funded Curtin University with $737,690 to develop and optimize 3D technology for bioprinting skin tissue directly onto model wounds as a prelude to human skin restoration.

The anticipated rise in chronic diseases is set to be a driving factor in the prospective growth of the 3D bioprinting market. Chronic diseases, persisting over extended periods - typically three months or more, and often for a person's lifetime - have increasingly utilized 3D bioprinting for creating tissue models, aiding in chronic disease research and potential organ replacement therapies. For example, as per the World Health Organization's September 2022 report, approximately 41 million deaths globally annually, representing 74% of fatalities, are attributed to non-communicable diseases (NCDs) or chronic diseases. This alarming figure includes 17.9 million deaths from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2 million deaths from diabetes. Consequently, the upsurge in chronic diseases is a significant driver behind the growth of the 3D bioprinting market.

Leading companies in the 3D bioprinting market are focusing on developing next-generation bioprinters for use in tissue engineering and regenerative medicine. A bio 3D printer is a specialized device that constructs biological structures, such as tissues and organs, using bioinks made from living cells or biocompatible materials. For example, in November 2022, Avay Biosciences, an India-based healthcare company, launched the Mito Plus. This printer facilitates the creation of complex human tissues, addressing critical challenges like organ shortages and improving drug testing methodologies. Key features include precise temperature control (ranging from 4°C to 80°C), a dual-extruder system for multiple biomaterials, inbuilt UV curing to enhance tissue quality, and HEPA filters to maintain a sterile printing environment.

Major companies in the 3D bioprinting market are focusing on developing innovative technological solutions, such as 3D bioprinters, to improve precision and efficiency in tissue engineering and regenerative medicine. 3D bioprinters are devices that utilize bioinks containing living cells to produce three-dimensional tissue and organ structures for medical research and regenerative medicine applications. For example, in June 2024, Tethon 3D, a US-based developer of ceramic powder and metal-polymer products, introduced the Bison Bio DLP 3D bioprinter, marking its entry into the bioprinting market. Developed in collaboration with Carima, this advanced printer offers adjustable build sizes (30 × 20 mm, 57 × 32 mm, and 96 × 54 mm) and is compatible with Tethon’s proprietary LAP photoinitiator and GelMA hydrogel bioink, crucial for bioprinting living tissues. Measuring 24 × 24 × 24 inches and weighing 75 lbs, the Bison Bio is priced at $19,950 and aims to drive advancements in healthcare by enabling the creation of complex tissues and organs for biomedical research, supporting personalized medicine and regenerative therapies.

In May 2022, BICO, a biotechnology company from Sweden focused on 3D bioprinting technology, announced the acquisition of Allegro 3D, Inc. for $6 million. This acquisition is intended to support BICO's strategic objectives by incorporating advanced technology and broadening its market reach. Allegro 3D, Inc., located in San Diego, specializes in light-based printing technology, which enhances BICO’s current capabilities.

Major companies operating in the 3D bioprinting market include Organovo Holdings Inc., Allevi Inc., Cellink AB, Aspect Biosystems Ltd., 3D Systems Corporation, Cyfuse Biomedical KK, EnvisionTEC GmbH, Poietis SA, TeVido BioDevices, Nano3D Biosciences Inc., Digilab Inc., RegenHU Ltd., GeSiM mbH, Advanced Solutions Life Sciences LLC, Regenovo Biotechnology Co. Ltd., Regemat 3D S.L., Bio3D Technologies, Stratasys Ltd., ROKIT Healthcare Co. Ltd., Inventia Life Science Pvt. Ltd., Vivax Bio LLC, GE HealthCare Technologies Inc., 3D Biotek LLC, Nuclera Nucleics Ltd., 3D Fortify Inc., Carbon Inc., Divergent Technologies Inc., Markforged Inc., SprintRay Inc., 3D Bio Corp, 3D Bioprinting Solutions, BICO Group AB, CollPlant Biotechnologies Ltd., Shining 3D Tech Co. Ltd., 3Dynamic Systems Ltd., Modern Meadow Inc.

3D Bioprinting, a form of additive manufacturing, involves the layer-by-layer printing of live structures that emulate the behavior of living systems. This process utilizes cells and biocompatible materials, commonly referred to as bio-inks. The primary application of 3D bioprinting materials is in drug research, and more recently, in the creation of cell scaffolds for repairing damaged ligaments and joints.

The key components in 3D bioprinting include 3D bioprinters and bio-inks. 3D bioprinters employ three-dimensional technology along with biocompatible materials to replicate various body parts, facilitating the bioprinting of tissues, bones, organs, blood vessels, and biomedical components. The materials involved in the process encompass living cells, hydrogels, extracellular matrices, and others. The application of 3D bioprinting extends to research and clinical settings, among others, and finds implementation in diverse sectors such as research organizations, academic institutes, biopharmaceutical companies, hospitals, and more.

The 3D bioprinting market research report is one of a series of new reports that provides 3D bioprinting market statistics, including 3D bioprinting industry global market size, regional shares, competitors with a 3D bioprinting market share, detailed 3D bioprinting market segments, market trends and opportunities, and any further data you may need to thrive in the 3D bioprinting industry. This 3D bioprinting market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

North America was the largest region in the 3D bioprinting market in 2024. The Asia-Pacific is expected to be the fastest-growing region in the 3D bioprinting market during the forecast period. The regions covered in the 3D bioprinting market report analysis are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the 3D bioprinting market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The 3D bioprinting market consists of sales of extrusion-based bioprinting, inkjet-based bioprinting, laser-assisted bioprinting, and stereolithography bioprinting. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.